TCR2 THERAPEUTICS INC.·4

Dec 10, 4:30 PM ET

Hofmeister Robert 4

4 · TCR2 THERAPEUTICS INC. · Filed Dec 10, 2021

Insider Transaction Report

Form 4
Period: 2021-12-09
Hofmeister Robert
Chief Scientific Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-12-09+100,000100,000 total
    Exercise: $5.21Exp: 2031-12-08Common Stock (100,000 underlying)
Holdings
  • Common Stock

    45,850
Footnotes (1)
  • [F1]25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION